In this new study, WIESLAB® Complement System Classical Pathway (CP) and WIESLAB® Complement System Alternative Pathway (AP) assays were used to determine the pharmacodynamic profile of SAR445088 in the first-in-human trial of this anti-C1s humanized monoclonal antibody.
According to the study, SAR445088 was well-tolerated and had variable pharmacokinetic (PK) and pharmacodynamic (PD) profiles after ascending doses and multiple doses in humans.